1 / 3

V3 region: remarkable variability  “structurally conserved” motifs  vaccine

Amir Maksyutov amaksyutov@yandex.ru. Candidate vaccine capable of eliciting broadly reacting antibody response to structurally conserved areas on the HIV-1 V3 region. V3 region: remarkable variability  “structurally conserved” motifs  vaccine

preston-donovan
Télécharger la présentation

V3 region: remarkable variability  “structurally conserved” motifs  vaccine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Amir Maksyutov amaksyutov@yandex.ru Candidate vaccine capable of eliciting broadly reacting antibody response to structurally conserved areas on the HIV-1 V3 region • V3 region: remarkable variability  “structurally conserved” motifs vaccine • Chimeric Peptide Library (CPL) mimic the antigenic variety of V3 region • Immunization with CPL Abs to “structurally conserved” V3 motifs

  2. Amir Maksyutov amaksyutov@yandex.ru RESULTS • CPL was recognized by HIV-1+ • CPL: immunization strong Ab response • Representative peptide panel (RPP): 30 very rare and 5 major variants • strong reactivity with all RPP peptides • broad specificity  covering as very rare as major V3 antigenic variants •  Ab response to the “structurally conserved” V3 motifs

  3. Amir Maksyutov amaksyutov@yandex.ru CONCLUSIONS& PROSPECT • Clinical trial for a mixture of five V3 peptides • Murine HIV-1 challenge system  anti-CPL sera – the most protective we have observed • Broad specificity • Abs to the “structurally conserved” V3 motifs • Design novel vaccine candidates  potentially protective broad Ab response • Therapeutic HIV/AIDS vaccine development

More Related